194 related articles for article (PubMed ID: 15653692)
1. Signaling mechanisms responsible for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells.
Li H; Ye X; Mahanivong C; Bian D; Chun J; Huang S
J Biol Chem; 2005 Mar; 280(11):10564-71. PubMed ID: 15653692
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells.
Mahanivong C; Chen HM; Yee SW; Pan ZK; Dong Z; Huang S
Oncogene; 2008 Feb; 27(9):1273-80. PubMed ID: 17724468
[TBL] [Abstract][Full Text] [Related]
3. The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion.
Jeong KJ; Park SY; Cho KH; Sohn JS; Lee J; Kim YK; Kang J; Park CG; Han JW; Lee HY
Oncogene; 2012 Sep; 31(39):4279-89. PubMed ID: 22249252
[TBL] [Abstract][Full Text] [Related]
4. Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway.
Estrella VC; Eder AM; Liu S; Pustilnik TB; Tabassam FH; Claret FX; Gallick GE; Mills GB; Wiener JR
Int J Oncol; 2007 Aug; 31(2):441-9. PubMed ID: 17611702
[TBL] [Abstract][Full Text] [Related]
5. Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway.
Bian D; Su S; Mahanivong C; Cheng RK; Han Q; Pan ZK; Sun P; Huang S
Cancer Res; 2004 Jun; 64(12):4209-17. PubMed ID: 15205333
[TBL] [Abstract][Full Text] [Related]
6. Lysophosphatidic acid promotes cell invasion by up-regulating the urokinase-type plasminogen activator receptor in human gastric cancer cells.
Kim MH; Park JS; Chang HJ; Baek MK; Kim HR; Shin BA; Ahn BW; Jung YD
J Cell Biochem; 2008 Jun; 104(3):1102-12. PubMed ID: 18247343
[TBL] [Abstract][Full Text] [Related]
7. Rel transcription factors contribute to elevated urokinase expression in human ovarian carcinoma cells.
Reuning U; Guerrini L; Nishiguchi T; Page S; Seibold H; Magdolen V; Graeff H; Schmitt M
Eur J Biochem; 1999 Jan; 259(1-2):143-8. PubMed ID: 9914486
[TBL] [Abstract][Full Text] [Related]
8. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells.
Pustilnik TB; Estrella V; Wiener JR; Mao M; Eder A; Watt MA; Bast RC; Mills GB
Clin Cancer Res; 1999 Nov; 5(11):3704-10. PubMed ID: 10589790
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase C induces motility of breast cancers by upregulating secretion of urokinase-type plasminogen activator through activation of AP-1 and NF-kappaB.
Sliva D; English D; Lyons D; Lloyd FP
Biochem Biophys Res Commun; 2002 Jan; 290(1):552-7. PubMed ID: 11779207
[TBL] [Abstract][Full Text] [Related]
10. Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner.
Nguyen DH; Catling AD; Webb DJ; Sankovic M; Walker LA; Somlyo AV; Weber MJ; Gonias SL
J Cell Biol; 1999 Jul; 146(1):149-64. PubMed ID: 10402467
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of lysophosphatidic acid receptor-2 expression by RNA interference decreases lysophosphatidic acid-induced urokinase plasminogen activator activation, cell invasion, and migration in ovarian cancer SKOV-3 cells.
Wang GL; Wen ZQ; Xu WP; Wang ZY; Du XL; Wang F
Croat Med J; 2008 Apr; 49(2):175-81. PubMed ID: 18461672
[TBL] [Abstract][Full Text] [Related]
12. Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells.
Hu YL; Albanese C; Pestell RG; Jaffe RB
J Natl Cancer Inst; 2003 May; 95(10):733-40. PubMed ID: 12759391
[TBL] [Abstract][Full Text] [Related]
13. Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-kappaB pathway by lysophosphatidic acid, an ovarian cancer-activating factor.
Chou CH; Wei LH; Kuo ML; Huang YJ; Lai KP; Chen CA; Hsieh CY
Carcinogenesis; 2005 Jan; 26(1):45-52. PubMed ID: 15471896
[TBL] [Abstract][Full Text] [Related]
14. Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras.
Lengyel E; Stepp E; Gum R; Boyd D
J Biol Chem; 1995 Sep; 270(39):23007-12. PubMed ID: 7559439
[TBL] [Abstract][Full Text] [Related]
15. Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator.
Sliva D; Rizzo MT; English D
J Biol Chem; 2002 Feb; 277(5):3150-7. PubMed ID: 11689575
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of nuclear factor-kappaB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma.
Chan CF; Yau TO; Jin DY; Wong CM; Fan ST; Ng IO
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4140-9. PubMed ID: 15217951
[TBL] [Abstract][Full Text] [Related]
17. Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma.
Ahmed N; Riley C; Oliva K; Rice G; Quinn M
Br J Cancer; 2005 Apr; 92(8):1475-85. PubMed ID: 15798771
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
19. The NF-κB pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC).
Dutta S; Wang FQ; Wu HS; Mukherjee TJ; Fishman DA
Gynecol Oncol; 2011 Oct; 123(1):129-37. PubMed ID: 21782227
[TBL] [Abstract][Full Text] [Related]
20. MUC1 protein induces urokinase-type plasminogen activator (uPA) by forming a complex with NF-κB p65 transcription factor and binding to the uPA promoter, leading to enhanced invasiveness of cancer cells.
Mori Y; Akita K; Tanida S; Ishida A; Toda M; Inoue M; Yashiro M; Sawada T; Hirakawa K; Nakada H
J Biol Chem; 2014 Dec; 289(51):35193-204. PubMed ID: 25371209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
